Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Veterans Affairs Department Expands Coverage Amid Patient Safety Concerns
The Associated Press reports that the VA "opened the doors of its health care system Monday to about 266,000 nondisabled veterans with moderate incomes, some of whom have been shut out of those benefits. The veterans eligible are from a category known as "Priority 8." They have no illnesses or injuries attributed to their military service, and they earn more than the average wage in their communities." The AP notes that such veterans were previously denied enrollment because of a cost-savings move in 2003, but the VA is expanding eligibility by raising income restrictions from about $29,000 to $32,000, which is adjusted for the cost of living. The effort represents part of President Barack Obama"s campaign promise to bring all veterans into the VA"s system. The AP notes that: "In 1996, Congress ordered the agency to open health care to nearly all veterans, but lawmakers also gave the VA secretary the authority to suspend enrollments" (Hefling, 6/15).
generic viagra online
UCB's Cimzia(R) Approved In The U.S. For Adult Patients Suffering From Moderate To Severe Rheumatoid Arthritis
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the U.S. Food and Drug Administration (FDA) has approved Cimzia®, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia® (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB. Cimzia is one of several products which utilize Enzon"s PEGylation technology, including PEG-INTRON®, Macugen®, and Pegasys®.
News of the day
Xenophon Attacks South Australian Aged Care Nurses
Australian Nursing Federation (ANF) Federal Secretary Ged Kearney said comments made by Senator Nick Xenophon today display a lack of understanding of the award modernisation process and the benefits this process brings to nursing staff, employers and the aged care industry.
Sexual Health

Senesco Presents Pre-Clinical Multiple Myeloma Data At The 12th Annual Meeting Of The American Society Of Gene Therapy

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) announced that Richard Dondero, Vice President of Research and Development, will be presenting pre-clinical data from Senesco"s multiple myeloma studies at the 12th Annual Meeting of the American Society of Gene Therapy, which is being held at the San Diego Convention Center in San Diego, CA, from Wednesday, May 27th through to Saturday, May 30th, 2009. Mr. Dondero will be presenting in the afternoon session on Thursday, May 28th. The American Society of Gene Therapy (ASGT) is a non-profit medical and professional organization that represents researchers and scientists devoted to the discovery of new gene and cell therapies. ASGT was established in 1996, and with more than 2,000 members in the United States and worldwide, ASGT is the largest association of individuals involved in gene and cell therapeutics. About Senesco Technologies, Inc. Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners" products. Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate a financing; the development of the Company"s gene technology; the approval of the Company"s patent applications; the successful implementation of the Company"s research and development programs and joint ventures; the success of the Company"s license agreements; the acceptance by the market of the Company"s products; the success of the Company"s preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company"s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company"s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Senesco Technologies, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009